COVID-19

Publications and Guidelines

31.03.2020

Preventing a covid-19 pandemic: ACE inhibitors as a potential risk factor for fatal Covid-19

Sommerstein/Gräni from the Inselspital were questioning whether ACE inhibitors upregulate ACE2, the entry receptor for Sars-CoV2 and may worsen the course?

#prevention #treatment #cardiovascular #diabetes #cardiology
31.03.2020

Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers

Due to the concern of patients and healthcare providers regarding uncertainties with ACEI/ARBs in Covid-19, a statement was released: ACEI/ARBs should be continued and treatment should not be changed as no evidence is available that they do harm in Covid-19. ACEI/ARBs should be given according to established guidelines.

#guidelines #cardiology
31.03.2020

Recommendations for Endotracheal Intubation of COVID-19 Patients

Anesthesia induction is a precedure with a high risk of aerosolization of SARS-CoV-2. This article discribes how anesthesia induction should be modified in order to minmize this risk. This article is short and reflects the positions of the major societies

#treatment #guidelines #anaesthesiology
31.03.2020

COVID-19 pandemic: triage for intensive-care treatment under resource scarcity

Although not a being a scientific paper, this special article provides decision guidance for the allocation of ICU treatment in the face of scarce ressources with a potentially upcoming wave of COVID-19 patients requiring ICU support in Switzerland

#treatment #guidelines #ICU
30.03.2020

Joint Statement on Multiple Patients Per Ventilator

Several countries that face a mismatch between existing ventilatory infrastructure and demand for ventilator support of critical COVID-19 patients in ICU start developing custom-made solutions to overcome this problem. Some of these include ventilating two or more patients with the same ventilator. The Anaesthesia Safety Foundation (APSF) has released a statement that discourages these modifications and provides solid arguments against such solutions. This statement has been endorsed by several other major organizations.

#treatment #guidelines #ICU #anaesthesiology
30.03.2020

Not wearing masks to protect against coronavirus is a ‘big mistake,’ top Chinese scientist says

Interesting interview with George Gao, head of the Chinese Center for Disease Control and Prevention

#prevention #general #epidemiology
30.03.2020

Clinical and immunologic features in severe and moderate Coronavirus Disease 2019

Analyse von immunologischen Faktoren im peripheren Blut bei 21 Paitenten mit mittelschwerer bis schwerer COVID-Infektion zum Zeitpunkt des Spitaleintritts. Patienten mit schwerem Verlauf (SpO2<93%, Tachypnoe oder beatmungspflichtig) wiesen höhere Werte an IL-2R, IL-6, IL-10 und TNF-a auf, zudem eine absolute Lymphopenie, welche vorwiegend auf eine Reduktion von CD4+ und CD8+ T Zellen zurückgeführt wurde.

Comment Taskforce Knowledge-Management Covid-19

Wenngleich diese Parameter nicht spezifisch für COVID19 Infektionen sind und im Allgemeinen Ausdruck einer schweren viralen Infekten, könnten sie zur frühzeitigen Beurteilung von Therapiebedarf und Einschätzung des Outcomes bei COVID19-erkrankten Patienten berücksichtigt werden.

#treatment #ICU #immunoresponses
30.03.2020

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Safety and effectivity of covalescent plasma in 5 patients with ventilation-dependent COVID infection

#treatment #ICU
30.03.2020

Convalescent Plasma to Limit Coronavirus Associated Complications: An Open Label, Phase 2A Study of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19

Open label, single arm trial with covalescent plasma, 1-2 units with anti-CoV2 titer >1:64. Endpoint: RNA Change, ICU admision, hospital Mortality, Hospital Lenthg

#treatment #ICU
30.03.2020

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Patients shed virus in saliva more than 21 days after disease onset, Peak Viral load is positive correlated with age and is independent from disease severity. The vast majority of patients develop antibodies with neutralizing activity in vitro.

#diagnosis #general